Patient characteristic | Placebo (n=221) | Rofecoxib 50 mg (n=219) | Naproxen 500 mg twice daily (n=220) |
---|---|---|---|
NSAIDs, non-steroidal antiinflammatory drugs; GI, gastrointestinal; PUBs, gastrointestinal perforations, ulcers, or bleeding episodes. | |||
Female (%) | 82 | 86 | 78 |
Mean age (y) | 51 | 53 | 51 |
≥65 years (%) | 16 | 20 | 16 |
% from USA | 22 | 21 | 22 |
% White | 48 | 52 | 52 |
History of upper GI events (PUBs) (%) | 10 | 11 | 14 |
H pylori positive (%) | 61 | 61 | 57 |
% with baseline gastroduodenal erosions | 11 | 13 | 14 |
Tobacco use (%) | 38 | 34 | 40 |
Corticosteroids (%) | 61 | 56 | 59 |
Prior NSAID use (%) | 70 | 68 | 57 |